Top Page
Percheron Therapeutics
(OTC:PER)
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Percheron Therapeutics Business Overview & Revenue Model
Percheron Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -67.98K | -67.98K | -79.42K | -95.20K | -89.22K | -103.32K |
| EBITDA | -16.27M | -16.27M | -11.84M | -13.25M | -7.52M | -8.58M |
| Net Income | -14.92M | -14.92M | -11.92M | -11.38M | -5.81M | -8.06M |
Balance Sheet | ||||||
| Total Assets | 12.44M | 12.44M | 14.53M | 12.84M | 22.44M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 10.17M | 10.17M | 11.87M | 10.97M | 19.23M | 6.02M |
| Total Debt | 25.86K | 25.86K | 39.87K | 142.10K | 227.40K | 306.85K |
| Total Liabilities | 2.43M | 2.43M | 5.17M | 2.87M | 1.30M | 1.27M |
| Stockholders Equity | 10.00M | 10.00M | 9.36M | 9.98M | 21.14M | 5.73M |
Cash Flow | ||||||
| Free Cash Flow | -15.65M | -15.65M | -10.12M | -8.18M | -7.81M | -5.84M |
| Operating Cash Flow | -15.64M | -15.64M | -10.12M | -8.15M | -7.81M | -5.83M |
| Investing Cash Flow | -7.24K | -7.24K | -3.61K | -29.29K | -3.91K | -8.35K |
| Financing Cash Flow | 13.95M | 13.95M | 11.02M | -85.30K | 21.02M | 7.80M |
Percheron Therapeutics Peers Comparison
Percheron Therapeutics Corporate Events
Percheron Therapeutics has disclosed a change in director Ben Gil Price’s holdings, following his on-market purchase of 2 million fully paid ordinary shares on 22 December 2025 for approximately A$17,220, increasing his total shareholding to 7,999,805 shares while his options position remains unchanged. The transaction, which did not occur during a closed period and involved no change in contractual interests, signals increased financial alignment between the director and shareholders and provides additional transparency to investors regarding insider confidence in the company’s prospects.
Percheron Therapeutics has disclosed that director James Garner increased his direct holding in the company by purchasing 1 million fully paid ordinary shares on-market between 17 and 19 December 2025 for a total consideration of $8,500. Following the transaction, Garner holds 53.5 million ordinary shares along with a substantial portfolio of unquoted options, a move that signals continued insider confidence and may be closely watched by shareholders and market participants as an indicator of management’s outlook on the company’s prospects.
Percheron Therapeutics has released an updated corporate presentation that includes new information on its program HMBD-002 and an overview of its financial position. The presentation aims to inform shareholders and investors about the company’s progress and future plans, potentially impacting its operations and industry positioning.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics reported positive clinical and preclinical data for its drug HMBD-002, showing a favorable safety profile and potential efficacy in treating various cancers. The company is advancing to a phase II clinical trial and has completed the transfer of the IND application with the FDA, positioning HMBD-002 for further development. Additionally, Percheron received a significant R&D tax rebate and appointed two senior executives to support the drug’s progress.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics Limited announced the results of its Annual General Meeting, where all resolutions were decided by a poll. Notably, the adoption of the 2025 Remuneration Report was supported by more than 75% of votes, leading to the withdrawal of the Conditional Spill Resolution. This outcome reflects strong shareholder support and suggests stability in the company’s governance, potentially influencing its strategic direction and investor confidence.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics Limited announced its presentation for the Annual General Meeting, highlighting its progress and plans for its lead program, HMBD-002, which targets advanced cancer. The company aims to commence further clinical trials in 2026, signaling a significant step in its development strategy and potential impact on the oncology and rare disease markets.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.